Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
26 Octubre 2023 - 7:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced that it will
report third quarter 2023 financial results on Thursday, November
2, 2023, after the close of the market. The announcement will be
followed by a live audio webcast and conference call at 2:00 PM
Pacific Time/5:00 PM Eastern Time.
Listen-Only Webcast The listen-only webcast
will be made available on the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. A replay will be available on the Company's website
for approximately 30 days.
Conference Call Registration If you would like
the option to ask a question on the conference call, please use
this link to register. Upon registering for the conference call,
you will receive a personal PIN to access the call.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on X (formerly Twitter)
and LinkedIn.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Corporate Affairs & Brand Strategy Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Allogene Therapeutics (NASDAQ:ALLO)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024